Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw Transplantation Center experience

Transplant Proc. 2002 Mar;34(2):551-2. doi: 10.1016/s0041-1345(01)02842-1.
No abstract available

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Daclizumab
  • Female
  • Graft Rejection / drug therapy
  • Graft Rejection / epidemiology*
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Kidney Transplantation / immunology*
  • Male
  • Middle Aged
  • Pancreas Transplantation / immunology*
  • Poland
  • Renal Dialysis / statistics & numerical data
  • Retrospective Studies
  • Risk Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab